We are live on ! Find out more
AGN

Allergan plc
AGN

Delisted

AGN was delisted on the 8th of May, 2020.

1,115 hedge funds and large institutions have $67.3B invested in Allergan plc in 2017 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 467 increasing their positions, 409 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 79

14% more repeat investments, than reductions

Existing positions increased: 467 | Existing positions reduced: 409

9% more call options, than puts

Call options by funds: $2.21B | Put options by funds: $2.03B

1% more funds holding

Funds holding: 1,1041,115 (+11)

2% less capital invested

Capital invested by funds: $68.4B → $67.3B (-$1.09B)

5% less funds holding in top 10

Funds holding in top 10: 7773 (-4)

Holders
1,115
Holders Change
+11
Holders Change %
+1%
% of All Funds
27.8%
Holding in Top 10
73
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-5.19%
% of All Funds
1.82%
New
101
Increased
467
Reduced
409
Closed
79
Calls
$2.21B
Puts
$2.03B
Net Calls
+$184M
Net Calls Change
+$916M
Name Holding Trade Value Shares
Change
Change in
Stake
HIMCH
251
Hartford Investment Management Co (HIMCO)
Connecticut
$19M -$695K -2,957 -4%
FAF
252
Fjarde Ap-fonden
Sweden
$19M +$186K +790 +1%
CA
253
Claar Advisors
New York
$18.9M +$5.22M +22,222 +40%
SH
254
Sandia Holdings
Connecticut
$18.7M -$1.99M -8,466 -10%
PA
255
Pinnacle Associates
New York
$18.7M +$219K +931 +1%
Capital World Investors
256
Capital World Investors
California
$18.6M +$2.94M +12,500 +20%
Zurich Cantonal Bank
257
Zurich Cantonal Bank
Switzerland
$18.6M -$4.64M -19,761 -21%
Natixis Advisors
258
Natixis Advisors
Massachusetts
$18.4M +$382K +1,624 +2%
RJFSA
259
Raymond James Financial Services Advisors
Florida
$18.3M +$882K +3,752 +5%
LOAMS
260
Lombard Odier Asset Management (Switzerland)
Switzerland
$18M +$1.14M +4,854 +7%
FIM
261
Foresters Investment Management
New York
$17.9M +$947K +4,031 +6%
PIA
262
Piedmont Investment Advisors
North Carolina
$17.5M +$179K +763 +1%
HP
263
Hikari Power
Japan
$17.4M
GI
264
GAMCO Investors
Connecticut
$17.3M +$85.8K +365 +0.5%
Caisse de Depot et Placement du Quebec (CDPQ)
265
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$17.3M +$15.7M +66,955 +1,505%
JG
266
Jefferies Group
New York
$16.9M +$9.11M +38,748 +125%
JCM
267
Janney Capital Management
Pennsylvania
$16.9M -$530K -2,254 -3%
IA
268
Icon Advisers
Colorado
$16.7M +$2.37M +10,100 +17%
M&T Bank
269
M&T Bank
New York
$16.7M -$38.1K -162 -0.2%
CA
270
Commerzbank Aktiengesellschaft
Germany
$16.5M +$2.65M +11,291 +20%
CC
271
Carlson Capital
Texas
$16.1M +$15.6M +66,341 New
MME
272
Meag Munich Ergo
Germany
$16.1M -$5.11M -21,767 -25%
MSE
273
MUFG Securities EMEA
United Kingdom
$15.8M +$15.3M +65,000 New
EIM
274
ExxonMobil Investment Management
Texas
$15.7M -$2.34M -9,956 -13%
TAF
275
Tredje AP-fonden
Sweden
$15.5M -$1.08M -4,600 -7%

AGN Hedge Fund Activity: Q2 2017 in Review

1,115 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN) for Q2 2017, worth a combined $67.3B — down 1.6% from $68.4B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new AGN positions and 79 closed out — a net gain of 22 holders — while 467 added to existing stakes and 409 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $1.14B. The largest seller was Veritas Asset Management, exiting entirely with an estimated $761M sold.

  • 1,115 institutional investors held Allergan plc (AGN) as of Q2 2017, up from 1,104 in Q1 2017.
  • Funds reported $67.3B of Allergan plc stock for Q2 2017, down 1.6% quarter-over-quarter.
  • 101 funds opened new Allergan plc positions in Q2 2017 and 79 closed out, a net change of +22 holders.
  • The largest Allergan plc buyer in Q2 2017 was Janus Henderson Group, an estimated $1.14B added.
  • The largest Allergan plc seller in Q2 2017 was Veritas Asset Management, an estimated $761M sold.

Based on aggregated 13F filings for Q2 2017.